Załuski Michał, Stanuch Katarzyna, Karcz Tadeusz, Hinz Sonja, Latacz Gniewomir, Szymańska Ewa, Schabikowski Jakub, Doroż-Płonka Agata, Handzlik Jadwiga, Drabczyńska Anna, Müller Christa E, Kieć-Kononowicz Katarzyna
Department of Technology and Biotechnology of Drugs , Faculty of Pharmacy , Jagiellonian University Medical College , Kraków , Poland . Email:
PharmaCenter Bonn , Pharmaceutical Institute , Pharmaceutical Chemistry I , University of Bonn , An der Immenburg 4 , 53121 Bonn , Germany.
Medchemcomm. 2018 May 14;9(6):951-962. doi: 10.1039/c8md00070k. eCollection 2018 Jun 1.
A library of 27 novel amide derivatives of annelated xanthines was designed and synthesized. The new compounds represent 1,3-dipropyl- and 1,3-dibutyl-pyrimido[2,1-]purinedione-9-ethylphenoxy derivatives including a CHCONH linker between the (CH)-amino group and the phenoxy moiety. A synthetic strategy to obtain the final products was developed involving solvent-free microwave irradiation. The new compounds were evaluated for their adenosine receptor (AR) affinities. The most potent derivatives contained a terminal tertiary amino function. Compounds with nanomolar AR affinities and at the same time high water-solubility were obtained (A ( = 24-605 nM), A ( = 242-1250 nM), A ( = 66-911 nM) and A ( = 155-1000 nM)). 2-(4-(2-(1,3-Dibutyl-2,4-dioxo-1,2,3,4,7,8-hexahydropyrimido[2,1-]purin-9(6)-yl)ethyl)phenoxy)--(3-(diethylamino)propyl)acetamide () and the corresponding -(2-(pyrrolidin-1-yl)ethyl)acetamide () were found to be the most potent antagonists of the present series. While showed CYP inhibition and moderate metabolic stability, was found to possess suitable properties for applications. In an attempt to explain the affinity data for the synthesized compounds, molecular modeling and docking studies were performed using homology models of A and A adenosine receptors. The potent compound was used as an example for discussion of the possible ligand-protein interactions. Moreover, the compounds showed high water-solubility indicating that the approach of introducing a basic side chain was successful for the class of generally poorly soluble AR antagonists.
设计并合成了一个包含27种新型稠合黄嘌呤酰胺衍生物的文库。新化合物代表1,3 - 二丙基 - 和1,3 - 二丁基 - 嘧啶并[2,1 - ]嘌呤二酮 - 9 - 乙基苯氧基衍生物,在(CH)-氨基和苯氧基部分之间含有一个CHCONH连接基。开发了一种采用无溶剂微波辐射的合成策略来获得最终产物。对新化合物进行了腺苷受体(AR)亲和力评估。最有效的衍生物含有末端叔氨基官能团。获得了具有纳摩尔级AR亲和力且同时具有高水溶性的化合物(A = 24 - 605 nM)、A = 242 - 1250 nM)、A = 66 - 911 nM)和A = 155 - 1000 nM)。发现2-(4-(2-(1,3 - 二丁基 - 2,4 - 二氧代 - 1,2,3,4,7,8 - 六氢嘧啶并[2,1 - ]嘌呤 - 9(6)-基)乙基)苯氧基)--(3-(二乙氨基)丙基)乙酰胺()和相应的-(2-(吡咯烷 - 1 - 基)乙基)乙酰胺()是本系列中最有效的拮抗剂。虽然表现出CYP抑制和中等代谢稳定性,但发现具有适合应用的性质。为了解释合成化合物的亲和力数据,使用A和A腺苷受体的同源模型进行了分子建模和对接研究。以强效化合物为例讨论了可能的配体 - 蛋白质相互作用。此外,这些化合物显示出高水溶性,表明引入碱性侧链的方法对于一般难溶性AR拮抗剂类别是成功的。